ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer

Liu, Yang; Li, Yalun; Zhang, Min-Zhe; Chen, Dan; Leng, Yang; Wang, Juan; Han, Bo-Wei*; Wang, Ji哈尔滨医科大学
CANCER GENETICS2023-4DOI: 10.1016/j.cancergen.2023.02.001
10阅读
引用收藏
分享

摘要

Homologous recombination repair deficiency (HRD) results in a defect in DNA repair and is a frequent driver of tumorigenesis. Poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum-based therapies have increased theraputic effectiveness when treating HRD positive cancers. For breast cancer and ovairan can-cer HRD companion diagnostic tests are commonly used. However, the currently used HRD tests are based on high-depth genome sequencing or hybridization-based capture sequencing, which are technically com-plex and costly. In this study, we modified an existing method named shallowHRD, which uses low-pass whole genome sequencing (WGS) for HRD detection, and estimated the performance of the modified shal-lowHRD pipeline. Our shallowHRD pipeline achieved an AUC of 0.997 in simulated low-pass WGS data, with a sensitivity of 0.981 and a specificity of 0.964; and achieved a higher HRD risk score in clinical BRCA-deficient breast cancer samples ( p = 5.5 x 10 -5, compared with BRCA-intact breast cancer sam-ples). We also estimated the limit of detection the shallowHRD pipeline could accurately predict HRD status with a minimum sequencing depth of 0.1 x, a tumor purity of > 20%, and an input DNA amount of 1 ng. Our study demostrates using low-pass sequencing, HRD status can be determined with high accuracy using a simple approach with greatly reduced cost.

学科与关键词

关键词
Homologous recombination repairdeficiencyWhole genome sequencingCopy number variationsBreast cancer
相关
加载中…
  • ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis)
    Guo, Yuanli; He, Xinxin; Tan, Yanming; Liu, Junfeng; Chen, Huadong; Huang, Yi; Zhang, Chao; Tao, Ying*; Chen, Shan*Journal of Cancer Research and Clinical Oncology, 2023, 149(17): 15839-15844.
  • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
    Zhang, Meng; Ma, Si-Cong; Tan, Jia-Le; Wang, Jian; Bai, Xue; Dong, Zhong-Yi*; Zhang, Qing-Xue*Frontiers in Oncology, 2021, 11: 772604.被引 1
  • Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
    Guffanti, Federica; Mengoli, Ilaria; Damia, Giovanna*Frontiers in Oncology, 2024, 14: 1405361.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
CANCER GENETICS
发表日期
2023-04
卷期
第 272 卷
页码
1-6
DOI
10.1016/j.cancergen.2023.02.001
语言
ENGLISH
成果收录
SCIE
资助标注
Health Commission of Heilongjiang Province [2019-059]

作者

  • L

    Liu, Yang (第一作者)

    harbin med univ

  • L

    Li, Yalun

    yantai yuhuangding hosp

查看全部 8 位作者收起作者
  • Z

    Zhang, Min-Zhe

  • C

    Chen, Dan

  • L

    Leng, Yang

  • W

    Wang, Juan

  • H

    Han, Bo-Wei (通讯)

  • W

    Wang, Ji

    yantai yuhuangding hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417